Report shows Big Pharma's patent cliff in graphic detail

The Economist's analysis of Big Pharma's patent cliff woes is worth looking at if only for the accompanying graph and its plunging sales lines for Pfizer's ($PFE) Lipitor, Sanofi ($SNY) and Bristol-Myers Squibb's ($BMY) Plavix, Novartis' ($NVS) Diovan and Merck's ($MRK) Singulair. Report

Suggested Articles

The agency has granted Tecentriq a priority review in previously untreated NSCLC, setting up the Roche drug for an approval decision by June 19.

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

Allergan was willing to part with candidate brazikumab to pass FTC muster, but union and consumer groups say that sale won't amend antitrust worries.